Modality
Peptide
MOA
CFTRmod
Target
PRMT5
Pathway
Checkpoint
OCD
Development Pipeline
Preclinical
Feb 2017
→ Sep 2031
PreclinicalCurrent
NCT06633066
2,463 pts·OCD
2017-02→2031-09·Active
2,463 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-09-235.5y awayInterim· OCD
Trial Timeline
2017Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
Preclinical
Active
Catalysts
Interim
2031-09-23 · 5.5y away
OCD
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06633066 | Preclinical | OCD | Active | 2463 | SRI-4 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Nirarelsin | Johnson & Johnson | Phase 2 | PRMT5 | |
| LLY-4358 | Eli Lilly | Phase 3 | B7-H3 | |
| MRK-853 | Merck & Co | Phase 1 | PRMT5 | |
| Gelinaritide | AbbVie | Preclinical | FcRn | |
| Geliderotide | Sanofi | Phase 1/2 | PRMT5 | |
| Capifutibatinib | Sanofi | Approved | PRMT5 | |
| NVO-9615 | Novo Nordisk | Phase 2/3 | PRMT5 | |
| Suracagene | GSK | Phase 3 | PRMT5 | |
| Elrarapivir | Vertex Pharma | NDA/BLA | PRMT5 | |
| ALN-8757 | Alnylam | Preclinical | TIGIT |